• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to 'Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk'.

作者信息

Tisseverasinghe Steven, Tolba Marwan, Bahoric Boris, Saad Fred, Niazi Tamim

机构信息

Department of Radiation Oncology, Gatineau Hospital, McGill University, Gatineau, Quebec, Canada.

Department of Radiation Oncology, Dalhousie University, QEII Cancer Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.

出版信息

Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01049-z.

DOI:10.1038/s41585-025-01049-z
PMID:40473873
Abstract
摘要

相似文献

1
Reply to 'Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk'.对“线粒体功能障碍作为雄激素剥夺治疗诱导心血管风险的关键介质”的回复
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01049-z.
2
Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk.线粒体功能障碍是雄激素剥夺治疗诱导心血管风险的关键介质。
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01050-6.
3
Establishing the Frequency of the HLA Class II Pseudotumour 'at Risk' Genotype: A Pilot Epidemiologic Analysis.
ANZ J Surg. 2025 Jun 23. doi: 10.1111/ans.70232.
4
ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission.ADT-OH 通过组合靶向自噬和线粒体分裂对三阴性乳腺癌表现出抗转移活性。
Cell Death Dis. 2024 Jun 28;15(6):463. doi: 10.1038/s41419-024-06829-w.
5
Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.高剂量放疗治疗中高危前列腺癌行去势治疗的意义：文献复习。
Int J Urol. 2024 Oct;31(10):1068-1079. doi: 10.1111/iju.15535. Epub 2024 Jul 17.
6
Pharmacologic androgen deprivation and cardiovascular disease risk factors: a systematic review.药物去雄激素治疗与心血管疾病危险因素：系统评价。
Eur J Clin Invest. 2015 May;45(5):475-84. doi: 10.1111/eci.12431.
7
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益
J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.
8
Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature.新辅助雄激素剥夺治疗前生化反应对前列腺癌外照射放疗预后价值的系统评价。
Cancer Treat Rev. 2016 May;46:35-41. doi: 10.1016/j.ctrv.2016.03.016. Epub 2016 Apr 7.
9
Exercise to enhance cardiovascular health among black men with prostate cancer with androgen deprivation therapy (the POWER trial): A study protocol.针对接受雄激素剥夺治疗的前列腺癌黑人男性进行运动以增强心血管健康（POWER试验）：一项研究方案。
Contemp Clin Trials. 2025 Aug;155:107973. doi: 10.1016/j.cct.2025.107973. Epub 2025 May 30.
10
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.在转移性激素敏感性前列腺癌男性患者中，在雄激素剥夺治疗基础上加用阿比特龙：一项系统评价和荟萃分析。
Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8.

引用本文的文献

1
Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk.线粒体功能障碍是雄激素剥夺治疗诱导心血管风险的关键介质。
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01050-6.

本文引用的文献

1
Mitochondrial dysfunction as a crucial mediator of ADT-induced cardiovascular risk.线粒体功能障碍是雄激素剥夺治疗诱导心血管风险的关键介质。
Nat Rev Urol. 2025 Jun 5. doi: 10.1038/s41585-025-01050-6.
2
Revisiting the complex interactions in nocturnal polyuria: insights on OSA, ADH and ANP.重新审视夜间多尿中的复杂相互作用：对阻塞性睡眠呼吸暂停、抗利尿激素和心钠素的见解。
Nat Rev Urol. 2025 Apr 25. doi: 10.1038/s41585-025-01028-4.
3
Assessing the effects of prostate cancer therapies on cardiovascular health.评估前列腺癌治疗对心血管健康的影响。
Nat Rev Urol. 2025 Feb 26. doi: 10.1038/s41585-025-01002-0.
4
Mitochondrial dysfunction: mechanisms and advances in therapy.线粒体功能障碍：机制与治疗进展。
Signal Transduct Target Ther. 2024 May 15;9(1):124. doi: 10.1038/s41392-024-01839-8.
5
Molecular Mechanisms of the Neuroprotective Effect of Methylene Blue.亚甲蓝的神经保护作用的分子机制。
Biochemistry (Mosc). 2022 Sep;87(9):940-956. doi: 10.1134/S0006297922090073.
6
Cell-Free Mitochondrial DNA as a Potential Biomarker for Astronauts' Health.细胞游离线粒体 DNA 作为宇航员健康的潜在生物标志物。
J Am Heart Assoc. 2021 Nov 2;10(21):e022055. doi: 10.1161/JAHA.121.022055. Epub 2021 Oct 20.
7
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy.靶向代谢可塑性和灵活性动态用于癌症治疗。
Cancer Discov. 2020 Dec;10(12):1797-1807. doi: 10.1158/2159-8290.CD-20-0844. Epub 2020 Nov 2.
8
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications.心血管疾病中的线粒体功能障碍：转化研究的现状/临床及治疗意义
Med Res Rev. 2021 Jan;41(1):275-313. doi: 10.1002/med.21732. Epub 2020 Sep 21.
9
Mitochondrial 8-hydroxy-2'-deoxyguanosine and coronary artery disease in patients with type 2 diabetes mellitus.线粒体 8-羟基-2'-脱氧鸟苷与 2 型糖尿病患者的冠状动脉疾病。
Cardiovasc Diabetol. 2020 Feb 19;19(1):22. doi: 10.1186/s12933-020-00998-6.
10
Mitochondrial genetic medicine.线粒体遗传医学。
Nat Genet. 2018 Dec;50(12):1642-1649. doi: 10.1038/s41588-018-0264-z. Epub 2018 Oct 29.